Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc. Before that she served as company group chairman for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir) and Intelence® (etravirine), and she was responsible for oversight of a research and development portfolio including compounds targeting HIV, hepatitis C, and tuberculosis. Prior to joining Centocor, Inc., Ms. McHugh led the marketing communications for gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck Inc. She currently chairs the board of visitors for the Smeal College of Business of Pennsylvania State University as well as serves on the board of directors of Aerie Pharmaceuticals, Inc., Lantheus Holdings, Inc. and Trevena, Inc., all publicly held companies, and The New Xellia Group, a privately held company. She previously served on the board of directors for ViroPharma Inc., Epirus Biopharmaceuticals, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute. Ms. McHugh received her M.B.A. degree from St. Joseph’s University and her B.S. degree from Pennsylvania State University.
What is Julie McHugh's net worth?
The estimated net worth of Julie McHugh is at least $512,067.76 as of June 10th, 2024. Ms. McHugh owns 139,528 shares of Ironwood Pharmaceuticals stock worth more than $512,068 as of December 18th. This net worth estimate does not reflect any other investments that Ms. McHugh may own. Learn More about Julie McHugh's net worth.
How do I contact Julie McHugh?
Has Julie McHugh been buying or selling shares of Ironwood Pharmaceuticals?
Julie McHugh has not been actively trading shares of Ironwood Pharmaceuticals in the last ninety days. Most recently, Julie Mchugh sold 22,766 shares of the business's stock in a transaction on Monday, June 10th. The shares were sold at an average price of $6.29, for a transaction totalling $143,198.14. Following the completion of the sale, the director now directly owns 139,528 shares of the company's stock, valued at $877,631.12. Learn More on Julie McHugh's trading history.
Who are Ironwood Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Ironwood Pharmaceuticals?
During the last twelve months, Ironwood Pharmaceuticals insiders bought shares 2 times. They purchased a total of 17,604 shares worth more than $160,419.92. During the last twelve months, insiders at the biotechnology company sold shares 9 times. They sold a total of 366,471 shares worth more than $4,695,458.00. The most recent insider tranaction occured on November, 18th when SVP Andrew Davis sold 5,360 shares worth more than $21,868.80. Insiders at Ironwood Pharmaceuticals own 12.9% of the company.
Learn More about insider trades at Ironwood Pharmaceuticals. Information on this page was last updated on 11/18/2024.
